What is RNTX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.07B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for RNTX?

P/E (TTM) is n/a and 52-week range is $0.69 to $2.18 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s RNTX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for RNTX?

The company profile lists net income (TTM) near $-136M, EPS (TTM) near $-1.59 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Rein Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Austin, Texas, US, 85.5M shares outstanding, ISIN US00887A2042 when available from company profile and filing metadata.

Rein Therapeutics Inc

$RNTX

Health Care · Biotechnology

IR Run Scenarios

$0.79

+3.21%

Rein Therapeutics Inc

$RNTX

Health Care · Biotechnology

IR Run Scenarios

$0.79

+3.21%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. The company is headquartered in Austin, Texas and currently employs 10 full-time employees. The company went IPO on 2017-06-29. The firm's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).

Employees

10

Website

www.reintx.com/

IPO

2017-06-29

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US00887A2042

Headquarters

Austin, Texas, US

Shares outstanding

85.5M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

52.51%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. The company is headquartered in Austin, Texas and currently employs 10 full-time employees. The company went IPO on 2017-06-29. The firm's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).

Employees

10

Website

www.reintx.com/

IPO

2017-06-29

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)